SAN FRANCISCO, Jan 12 () - Amgen's research chief said the company is very confident about its experimental obesity drug ...

Pfizer is preparing for a market for obesity drugs on par with the booming business created by erectile dysfunction drug ...

A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase ...

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a ...

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 ...

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

One of the most notable breakout stories in the obesity drug market of 2025 was the clinical-stage biotech Structure ...

The clinical-stage biotech could see its shares plummet should there be any clinical setback.

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

ATLANTA, GA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Maxim Clinic, a leading provider of medical weight ...